Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/06/23 | $108,000,000 | Series B |
Acorn Bioventures Bioqube Ventures Eight Roads F-Prime Capital Partners Invus Janus Henderson Investors Omega Funds Piper Heartland Healthcare Capital Premji Invest RA Capital Management  Red Tree Venture Captial | undisclosed |
